Why insider trading matters?

If management teams do not own any relevant stakes in the companies they guide, they may not be focused on creating wealth for shareholders to the same degree, compared to those that see their personal wealth increase when share prices rise.

- Klaus Gugler, Economist
PDL BIOPHARMA, INC. (PDLI)
Sector: Healthcare; Industry: Biotechnology

PDL BioPharma, Inc. acquires, manages, and commercializes commercial stage pharmaceutical assets and late clinical stage pharmaceutical products in North America, Europe, Asia, and internationally. The company operates through Medical Devices, Strategic Positions, Pharmaceutical, and Income Generating Assets segments. The Pharmaceutical segment manufactures, markets, and sells prescription medicine products for the treatment of hypertension to wholesalers under the Tekturna and Tekturna HCT names in the United States, as well as under the Rasilez and Rasilez HCT names internationally. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2021-02-01 Silver Point Capital L.P. 10%-Owner Buy 187,061 $2.05 $383,475 No
2020-12-30 Silver Point Capital L.P. 10%-Owner Buy 6,325,213 $2.50 $15,813,032 No
2020-12-30 GRYSKA DAVID W Director Sell 20,000 $2.74 $54,800 No
2020-12-29 Silver Point Capital L.P. 10%-Owner Buy 631,600 $2.69 $1,696,234 No
2020-12-23 Silver Point Capital L.P. 10%-Owner Buy 1,565,000 $2.60 $4,067,400 No
2020-12-22 MCLAUGHLIN JOHN PETER Director Sell 327,934 $2.61 $855,774 No
2020-12-17 Silver Point Capital L.P. 10%-Owner Buy 1,748,000 $2.59 $4,521,780 No
2020-12-16 Stone Christopher Lewis VP, Gen. Counsel & Secretary Sell 200,000 $2.56 $512,000 No
2020-12-16 Monnet Dominique President and CEO Sell 500,000 $2.60 $1,300,000 No
2020-12-16 GRYSKA DAVID W Director Sell 75,000 $2.68 $201,000 No
2020-12-15 Silver Point Capital L.P. 10%-Owner Buy 2,090,000 $2.57 $5,369,300 No
2020-12-03 GRYSKA DAVID W Director Sell 75,000 $2.52 $189,000 No
2020-11-23 O'Farrell Elizabeth G. Director Sell 25,826 $2.44 $63,015 No
2020-11-23 GRYSKA DAVID W Director Sell 50,000 $2.43 $121,500 No
2020-11-18 O'Farrell Elizabeth G. Director Sell 63,291 $2.38 $150,696 No
2020-11-20 Bazaar Alan Lee Director Sell 33,435 $2.42 $81,003 Yes
2020-11-18 GRYSKA DAVID W Director Sell 150,000 $2.40 $359,500 No
2019-06-10 PDL BIOPHARMA, INC. 10%-Owner Buy 6,666,667 $4.50 $30,000,002 Yes
2017-03-24 GARCIA PETER S Vice President, CFO Buy 25,000 $1.98 $49,401 No
2016-08-09 GARCIA PETER S Vice President, CFO Buy 10,000 $3.00 $29,950 No
2015-12-15 GARCIA PETER S Vice President, CFO Buy 15,000 $3.50 $52,444 No
2015-12-07 Pietzke Steffen Controller and CAO Buy 20,590 $3.64 $74,931 No
2015-08-14 GARCIA PETER S Vice President, CFO Buy 20,000 $5.83 $116,502 No
2014-11-26 SELICK HAROLD E Director Buy 6,000 $8.08 $48,487 No
2011-03-15 Lindell Jody S Director Buy 374 $5.33 $1,992 No
2010-05-14 LARSON CHRISTINE R Vice President and CFO Buy 5,000 $5.71 $28,544 No
2010-04-30 LARSON CHRISTINE R Vice President and CFO Buy 10,000 $6.18 $61,830 No
2009-11-04 KLEIN JOSEPH III Director Sell 24,000 $8.33 $199,815 Yes
2009-06-15 Lindell Jody S Director Buy 3,000 $7.76 $23,280 No
2009-04-08 SANDMAN PAUL W Director Buy 10,000 $7.38 $73,822 No

Insider Smart

SIMON PROPERTY GROUP (SPG) - Bottom fishing the crash could be intimidating, but it can be easier if you know insiders are on your side. Aeppel Glyn, Director of SPG played safe and bought shares in May at $50, but it is not late at all, the stock is now $90.

Insider Smart

Axsome Therapeutics, Inc (AXSM) - AXSM shows the power of an #allgreen stock, no insider selling, great management great company, if you follow the insiders last year and pick up around $25, the 52 week high is $100+.